Evidence map›Paper›PMID 40621183›Full record

ReviewMaterials today. Bio2025

Organoids for tissue repair and regeneration.

Biao Yu, Dongyang Zhou, Fuxiao Wang, Xiao Chen, Mengmeng Li, Jiacan Su

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Biao YuMedEng-X Institutes, Shanghai University, Shanghai, 200444, China.
Dongyang ZhouMedEng-X Institutes, Shanghai University, Shanghai, 200444, China.
Fuxiao WangMedEng-X Institutes, Shanghai University, Shanghai, 200444, China.
Xiao ChenDepartment of Orthopedics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Mengmeng LiMedEng-X Institutes, Shanghai University, Shanghai, 200444, China.
Jiacan SuMedEng-X Institutes, Shanghai University, Shanghai, 200444, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue damage and dysfunction are common consequences of various diseases and trauma, severely impacting patients' quality of life. Organoids, three-dimensional cell clusters formed through the self-organization of stem cells, not only recapitulate the developmental processes of native tissues but also exhibit remarkable plasticity and long-term expansion capabilities, demonstrating potential to overcome limitations of conventional therapeutic approaches. Particularly in addressing challenges such as immune rejection and regenerative efficiency, organoid technology has shown distinct advantages. This review summarizes the applications of organoids in tissue repair, including the biological principles and cultivation strategies of organoid culture, as well as their specific applications and preclinical research progress across diverse tissues (e.g., brain, liver, intestine, bone). Additionally, it discusses current challenges in organoid technology, such as large-scale production, heterogeneity control, and clinical translation, while outlining future development directions.

Indexed as

Organoid derivativesOrganoidsRegenerative medicineStem cellsTissue repair

Identifiers

PMID40621183
PMCPMC12226387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.